In 2008, the WHO identified major depressive disorder (MDD) as the third leading contributor to the global burden of disease. About 3.8% of the global population experiences depression, with a prevalence of 5% among adults and 5.7% among those aged 60 and older. From 2010 to 2018, MDD prevalence in U.S. adults rose by 12.9%, from 15.5 million to 17.5 million, particularly among those aged 18–34. The economic burden of MDD increased by 37.9%, from $236.6 billion to $326.2 billion (2020 values). This study compares negative binomial regression (NB2) and XGBoost to predict healthcare expenses for MDD patients using the Medical Expenditure Panel Survey (MEPS) database (2017-2021). The study included 2,596 MDD patients, excluding those with other mental disorders. The average patient age was 52.5 years, 69% were women, and 65% were from high- and middle-income categories.
This report is a poster presentation of Axtria from ISPOR 2024.
Contact us at connect@axtria.com with any questions.